The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.
 
Alain Patrick Algazi
Stock and Other Ownership Interests - OncoSec; Valitor
Consulting or Advisory Role - Array BioPharma; OncoSec; Regeneron; Valitor
Research Funding - Acerta Pharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); Genentech (Inst); Idera (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); OncoSec (Inst); Oncosec (Inst); Sensei Biotherapeutics (Inst); Tessa Therapeutics (Inst)
Travel, Accommodations, Expenses - OncoSec
(OPTIONAL) Uncompensated Relationships - Merck; Sensei Biotherapeutics
 
Megan Othus
Consulting or Advisory Role - Cascadia Labs; Celgene; Glycomimetics
 
Adil Daud
Consulting or Advisory Role - BioNTech; Bristol-Myers Squibb; Incyte; Merck; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst)
 
Janice M. Mehnert
Honoraria - EMD Serono; Pfizer/EMD Serono
Consulting or Advisory Role - Amgen; Array BioPharma; Array BioPharma; Boehringer Ingelheim; Merck Sharp & Dohme; Sanofi/Regeneron
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Incyte (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); polynoma (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Merck Sharp & Dohme
Other Relationship - Amgen; Array BioPharma; Boehringer Ingelheim; EMD Serono; Merck; Merck
 
Thach-Giao Truong
No Relationships to Disclose
 
Robert Martin Conry
Speakers' Bureau - Amgen; Array BioPharma; Array BioPharma; Bristol-Myers Squibb; Merck; Novartis; Regeneron; Sanofi
 
Kari Lynn Kendra
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Gary C. Doolittle
Speakers' Bureau - Bristol-Myers Squibb; Merck; Novartis
 
Joseph I Clark
Employment - Bristol-Myers Squibb (I)
Consulting or Advisory Role - Clinigen Group
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Argos Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Nektar (Inst)
Travel, Accommodations, Expenses - Clinigen Group
 
Michael J. Messino
No Relationships to Disclose
 
Dennis Frederic Moore
No Relationships to Disclose
 
Christopher D. Lao
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore
Research Funding - Bristol-Myers Squibb; Dynavax Technologies; Genentech; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore
 
Bryan A. Faller
Consulting or Advisory Role - LEK
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; Genentech; Lilly; Merck; Novartis
 
Rangaswamy Govindarajan
No Relationships to Disclose
 
Amy K. Harker-Murray
Research Funding - Iovance Biotherapeutics (Inst)
 
Luke P. Dreisbach
No Relationships to Disclose
 
James Moon
No Relationships to Disclose
 
Kenneth F. Grossmann
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Bristol-Myers Squibb (I); Castle Biosciences; Novartis; Roche/Genentech
 
Roger Lo
Honoraria - Amgen
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); OncoSec (Inst)
 
Antoni Ribas
Stock and Other Ownership Interests - Advaxis; Arcus Biosciences; Compugen; CytomX Therapeutics; Five Prime Therapeutics; FLX Bio; ImaginAb; Lutris; Merus; PACT Pharma; Rgenix; Tango Therapeutics
Honoraria - Amgen; Chugai/Roche; Genentech/Roche; Merck Sharp & Dohme; Novartis; Sanofi
Consulting or Advisory Role - Amgen; Chugai Pharma; Merck; Novartis; Sanofi
Research Funding - Agilent (Inst); Bristol-Myers Squibb (Inst)